Description
Flexible QuantiGene assay formats
A variety of formats for different research needs.
Predefined, biologically relevant, and disease-defined panels.
Custom-blended and optimized panels deliver results tailored to the panel design of your choice.
Probe sets for the detection of individual targets.
Why QuantiGene?
QuantiGene RNA Assays measure gene expression directly from cell and whole blood lysates or tissue homogenates without the need to purify or amplify RNA. By measuring the RNA at the sample source, the assay avoids biases and variability inherent to extraction techniques and enzymatic manipulations. In addition, this direct measurement helps overcome issues with transcript degradation typically found in samples such as FFPE. Direct measurement is possible because target RNAs are captured through probe hybridization and quantified through branched DNA technology that amplifies the signal. The signal is read using a Luminex instrument for multiplex assays or a luminometer for single targets.
QuantiGene assays demonstrate high data concordance between multiple gene expression platforms (qPCR, microarrays), which allow the ability to switch technologies without having to repeat experiments.
Highlights and key advantages of the QuantiGene assay:
- Increase efficiency—harmonized gene and protein multiplex solution—QuantiGene and ProcartaPlex matched panels are complementary, highly correlative and run on the same Luminex platform, seamlessly integrated for unparalleled insights
- Excellent correlation with gold standard technology—between qPCR and QuantiGene
- Quantitate directly from crude samples—no need for RNA extraction, cDNA synthesis, or PCR amplification
- Detect low-abundance genes—exquisite sensitivity allows for the basal measurement of low-expression genes
- Works with difficult sample types—works with degraded and cross-linked RNA in FFPE tissues, with fresh or frozen tissues (animal or plant), whole blood, cultured cells, bacteria, and viruses
- Simple workflow—ELISA-like workflow using 96- or 384-well plates
- Large inventory of validated genes—select from over 22,500 genes to create pathways and disease-themed panels
- Customization—customize your panel, and receive your custom panel within 3–4 weeks
- Standardized formats to enable easy scale-up—96-well plate, 384-well plate, and plex-in-plex formats available
How the QuantiGene Assays work
Branched DNA technology
QuantiGene Plex and SinglePlex assays utilize branched DNA (bDNA) technology. bDNA technology utilizes sequential nucleic acid hybridization for a unique approach to RNA and DNA quantification by amplifying a reporter signal rather than the template. This measures the transcripts at physiological levels.
First, cells are lysed or tissue samples are homogenized to release the target RNA or DNA. Second, an oligonucleotide probe set is incubated with the target RNA or DNA. During this incubation, the probes cooperatively hybridize to the target. Third, signal amplification is performed via sequential hybridization of the bDNA pre-amplifier, amplifier, and labeled probe molecules to the target. Addition of a chemiluminescent substrate (singleplex assays) or fluorescent reporter (multiplex asssays) generates a signal directly proportional to the amount of target RNA or DNA present in the sample.
A pair of target-specific probe sets (Target Probe), approximately 20 nucleotides in length, hybridizes to contiguous sequences on the target RNA (or DNA). Signal amplification is achieved through successive hybridization of short oligonucleotide sequences to build the bDNA structure (bDNA “tree”), formed by Preamplifiers, Amplifiers, and Labeled Probe, resulting in excellent specificity, low background, and high signal-to-noise ratio.
Reviews
There are no reviews yet.